

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

<b>Application Number</b>	09780035
<b>Filing Date</b>	2001-02-09
<b>First Named Inventor</b>	Tariq Ghayur
<b>Art Unit</b>	1644
<b>Examiner Name</b>	Gambel, Phillip
<b>Attorney Docket Number</b>	BBC-084/US

Sheet

of

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	61	TAYLOR, LISA D. et al., A transgenic mouse that expresses a diversity of human sequence heavy and light chain immun, Nucleic Acids Research (1992), Vol. 20(23), pgs. 6287-6295	
	62	TISSI, LUCIANA et al., Role of Tumor Necrosis Factor Alpha, Interleukin-1B and Interleukin-6 in a mouse model of Group B, Infection and Immunity (1999), Vol. 67; 4545-4550	
	63	TRENTHAM, DAVID E. et al., Autoimmunity to Type II Collage: An Experimental Model of Arthritis, Journal of Exp. Med. (1977) Vol. 146, pgs. 857-868	
	64	TSUTSUI, HIROKO et al, Caspase-1 Independent, Fas/Fas/ Ligand-Mediated IL-18 Secretion from Macrophages Causes Acute liver injury in Mice, Immunity (1999) Vol. 11, pgs. 359-367	
	65	TSUTSUI, HIROKO et al., IL-18 Accounts for both TNF-a- and Fas Ligand-Mediated Hpatotoxic Pathways, Jour. of Immun., (1997), Vol. 159(8) pgs. 3961-3967	
	66	URLAUB GAIL et al., Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity, Pro. Natl. Acad. Sci. (1980) Vol. 77(7), pgs. 4216-4220	
	67	USHIO SHIMPEI et al., Cloning of the cDNA for Human IFN-γ-Inducing Factor, Expression in Escherichia coli, Journal of Immunology (1996) Vol. 156, pgs. 4274-4279	
	68	VAN NOSTRAND, WILLIAM E. et al., Protease nexin-II, a potent anti-chymotrypsin, shows identity to amyloid B-protein precursor, Nature (1989) Vol. 341, pgs. 546-551	
	69	WILDBAUM, GIZI et al., Neutralizing Antibodies to IF-γ-inducing Factor Prevent Experimental Autoimmune Encephalomyelitis, Journ. of Immun. (1998) Vol. 161(11), pgs. 6368-6374	
	70	WINTER, GREG et al., Making Antibodies by Phage Display Technology, Annu. Rev. of Immun. (1994), Vol. 12, pgs. 433-455	

Examiner Signature	/Phillip Gambel/	Date Considered	12/21/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./